Recent advances in the management of squamous cell carcinoma of the head and neck

References

• Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer 1 Clin. 50(1), 7–33 (2000).
   Google Scholar
• Clayman GL, Lippman SM, Laramore GE, Hong WK. Head and neck cancer. In: Cancer Medicine(Edition 5). Bast RC, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E (Eds.), BC Decker, Inc., Hamilton, USA, 1173–1220 (2000).
   Google Scholar
• Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer [See Comments]. N. Engl. Merl 328 (3), 184–194 (1993).
   Google Scholar
• ••A comprhensive review of head and neckcancer in general.
   Google Scholar
• Jacobs C, Lyman G, Velez-Garcia E et al. A Phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. Clin. Once]. 10(2), 257–263 (1992).
   PubMed Web of Science ®Google Scholar
• •The study compared combination of cisplatin and 5-fluorouracil with single agents in recurrent head and neck cancer. The response rate of the combination was higher than single agents, but the median survival rates were not different between the combination and single agents.
   Google Scholar
• Forastiere AA, Metch B, Schuller DE et al Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.j Gun. Oncol 10(8), 1245–1251 (1992).
   Google Scholar
• •The SWOG study compared cisplatin plus fluorouracil versus carboplatin plus 5-fluorouracil versus single-agent methotrexate in recurrent and metastatic head and neck cancer. The combination chemotherapy resulted in improved response rates, but was associated with an increased toxicity and no improvement in overall survival.
   Google Scholar
• Clavel M, Vermorken JB, Cognetti F et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A Phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann. 0=1 5(6), 521–526 (1994).
   Google Scholar
• •The study compared cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. The study showed that the CABO regimen has no advantage over the CF regimen. Both combinations showed improved response rates, but also more toxicity and no improvement in overall survival in comparison with cisplatin alone.
   Google Scholar
• Khuri FR, Shin DM, Glisson BS, Lippman SM, Hong WK. Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions. Semin. Oncol 27(4 Suppl. 8), 25–33 (2000).
   Google Scholar
• Schrijvers D, Vermorken JB. Update on the taxoids and other new agents in head and neck cancer therapy. CUI7: Opin. 0=1 10(3), 233–241 (1998).
   Google Scholar
• Milross CG, Mason IKA, Hunter NR, Chung WK, Peters LJ, Milas L. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel [See Comments]. Natl Cancer Inst. 88(18), 1308–1314 (1996).
   Google Scholar
• Belotti D, Vergani V, Drudis T et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res 2(11), 1843–1849 (1996).
   PubMed Web of Science ®Google Scholar
• Forastiere AA, Shank D, Neuberg D, Taylor SG, DeConti RC, Adams G. Final report of a Phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer82(11), 2270–2274 (1998).
   Google Scholar
• •The ECOG study evaluated paclitaxel in patients with advanced head and neck cancer in a Phase II setting. The response rate was 40% and the median duration of response was 4.5 months with a median survival of 9.2 months and a 1-year survival rate of 33%. The study concluded that paclitaxel is an active agent for the treatment of HNSCC.
   Google Scholar
• Smith RE, Thornton DE, Allen J. A Phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative laboratory studies. Semin. Oncol 22(3 Suppl. 6), 41–46 (1995).
   Google Scholar
• Benasso M, Numico G, Merlano M et al Phase I-II study of Taxol, cisplatin (CDDP) and fluorouracil (FU) in relapsed squamous cell carcinoma of the head and neck (SCC-HN). Proc. Am. Soc. Clin. Oncol Denver USA abstract 1415 (1997).
   Google Scholar
• Hainsworth JD, Meluch AA, Greco FA. Paclitaxel, carboplatin and long-term continuous 5-fluorouracil infusion in the treatment of upper aerodigestive malignancies: preliminary results of Phase II trial. Semin. Oncol 24(6 Suppl. 19), S19-38—S19-42 (1997).
   Google Scholar
• Hussain M, Gadgeel S, Kucuk O, Du W, Salwen W Ensley J. Paclitaxel, cisplatin and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck. Cancer 86 (11), 2364–2369 (1999).
   Google Scholar
• Shin DM, Glisson BS, Khuri FR et al. Phase II trial of paclitaxel, ifosfamide and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J: Clin. Oncol 16(4), 1325–1330 (1998).
   Google Scholar
• •The study assessed the activity and toxicity profile of combined paclitaxel, ifosfamide, and cisplatin (TIP) in patients with recurrent or metastatic HNSCC. TIP had major activity, with a 58% objective response rate, 17% complete response rate, durable complete responses (six of nine persisting) and relatively well-tolerated toxicity, with no toxic deaths.
   Google Scholar
• Forastiere AA, Leong T, Rowinsky E et al. Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. j Clin. 0=1 19(4), 1088–1095 (2001).
   Google Scholar
• •The ECOG study examined dose-response effects and the activity of pacfitaxel combined with cisplatin in patients with incurable HNSCC. Two aims of treatments were compared: Arm A, paclitaxel 200 mg/m2 (24 h infusion) + cisplatin 75 mg/m2 + granulocyte colony-stimulating factor or Arm B, paclitaxel 135 mg/m2 (24-hour infusion) + cisplatin 75 mg/m2. This phase III multicenter trial showed no advantage for high-dose paclitaxel and excessive hematologic toxicity associated with both regimens.
   Google Scholar
• Thodtmann F, Theiss F, Kemmerich M et al Clinical Phase II evaluation of paclitaxel in combination with cisplatin in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann. 0=1 9(3), 335–337 (1998).
   Google Scholar
• Stathopoulos GP, Rigatos S, Papakostas P, Fountzilas G. Effectiveness of paclitaxel and carboplatin combination in heavily pretreated patients with head and neck cancers. Eui:j Cancer 33 (11), 1780–1783 (1997).
   PubMed Web of Science ®Google Scholar
• Fountzilas G, Skarlos D, Athanassiades A et al Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck. A Phase II study conducted by the Hellenic Cooperative Oncology Group. Ann. Oncol 8(5), 451–455 (1997).
   Google Scholar
• Shin DM, Khuri FR, Glisson BS et al. Phase II study of paclitaxel, ifosfamide and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer91(7), 1316–1323 (2001).
   PubMed Web of Science ®Google Scholar
• •The study evaluated the antitumor activity and toxicity profile of a combination of paclitaxel, ifosfamide and carboplatin (TIC) in patients with recurrent or metastatic HNSCC. The TIC regimen had high antitumor activity in patients with recurrent or metastatic HNSCC, with a 59% major response rate (17% complete response rate with relatively durable complete responses). Neutropenic fever developed in 30% of the patients, the incidence of which might have been decreased by prophylactic antibiotics or hematopoietic growth factor support.
   Google Scholar
• Papadimitrakopoulou VA, Glisson BS, Khuri FR et al. Phase II study of induction chemotherapy with paclitaxel, ifosfamide and carboplatin in patients with locally advanced squamous cell carcinoma of the head and neck. Proc. Am. Soc. Clin. Oncol New Orleans, USA abstract 1659 (2000).
   Google Scholar
• Braakhuis BJ, Hill BT, Dietel M et al. In vitro antiproliferative activity of docetaxel (Taxotere), paclitaxel (Taxol) and cisplatin against human tumour and normal bone marrow cells. Anticancer Res. 14(1A), 205–208 (1994).
   Google Scholar
• Braakhuis BJ, Kegel A, Welters MJ. The growth inhibiting effect of docetaxel (Taxotere) in head and neck squamous cell carcinoma xenografts. Cancer Lett. 81(2), 151–154 (1994).
   PubMedGoogle Scholar
• Dreyfuss AI, Clark JR, Norris CM et al Docetaxel: an active drug for squamous cell carcinoma of the head and neck. j Gun. Oncol 14(5), 1672–1678 (1996).
   Google Scholar
• •Phase II study designed to evaluate the activity, safety and tolerability of docetaxel in patients with advanced, incurable or recurrent HNSCC who had not received prior palliative chemotherapy. Docetaxel has major activity against HNSCC.
   Google Scholar
• Schoffski P, Catimel G, Planting AS et al. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a Phase II study of the EORTC Early Clinical Studies Group. Ann. 0=1 10(1), 119–122 (1999).
   Google Scholar
• •Multicenter Phase II study in patients with locally advanced, recurrent or metastatic HNSCC to evaluate the antitumor efficacy and toxicity of the combination docetaxel and cisplatin. This combination is feasible and active in locally advanced, recurrent and metastatic HNSCC.
   Google Scholar
• Forastiere A, Glisson BS, Murphy B, O'Connell B. A Phase II study of docetaxel and cisplatin in patients with locally advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN), not curable by standard therapy. Proc. Am. Soc. Gun. awl, Los Angeles, USA abstract 1540 (1998).
   Google Scholar
• Janinis J, Papadakou M, Xidakis E et al. Combination chemotherapy with docetaxel, cisplatin and 5-fluorouracil in previously treated patients with advanced/ recurrent head and neck cancer: a Phase II feasibility study. Am j Gun. Oncol 23(2), 128–131 (2000).
   Google Scholar
• Colevas AD, Norris CM, Tishler RB et al. Phase II trial of docetaxel, cisplatin, fluorouracil and leucovorin as induction for squamous cell carcinoma of the head and neck [See Comments]. j Clin. 17(11), 3503–3511 (1999).
   Google Scholar
• •The study evaluated the toxicity and efficacy of a 4-day regimen of docetaxel, cisplatin, fluorouracil and leucovorin (TPFL4). The overall clinical response rate to TPFL4 was 93%, with 63% complete responses and 30% partial responses. TPFL4 has an acceptable toxicity profile in good performance-status patients. Modification of the 5-day TPFL regimen (TPFL5: shorter chemotherapy infusion time, earlier intervention with growth factors and antibiotics) led to fewer episodes of febrile neutropenia and hospitalization.
   Google Scholar
• Posner MR, Glisson B, Frenette G et al. Multicenter Phase I-II trial of docetaxel, cisplatin and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck.J Clin. Oncol 19(4), 1096–1104 (2001).
   Google Scholar
• •The Phase I-111, multi-institutional trial determined the maximum tolerated dose (MTD) of cisplatin in an induction chemotherapy regimen of docetaxel, cisplatin and fluorouracil (TPF) for HNSCC and evaluated the safety, tolerability and efficacy of the regimen at MTD. TPF induction chemotherapy can be delivered safely with a cisplatin dose of 100 mg/m2 in previously untreated patients with HNSCC. The regimen is associated with a high rate of primary site clinical and pathologic complete responses.
   Google Scholar
• Fernandes A, Hamburger AW, Gerwin BI. ErbB-2 kinase is required for constitutive stat 3 activation in malignant human lung epithelial cells. Int. j Cancer 83(4), 564–570 (1999).
   Google Scholar
• Song JI, Grandis JR. STAT signaling in head and neck cancer. Oncogene 19(21), 2489–2495 (2000).
   PubMedGoogle Scholar
• Reiss M, Stash EB, Vellucci VF, Zhou ZL. Activation of the autocrine transforming growth factor alpha pathway in human squamous carcinoma cells. Cancer Res. 51(23 Pt 1), 6254–6262 (1991).
   Google Scholar
• Hofer DR, Sherwood ER, Bromberg WD, Mendelsohn J, Lee C, Kozlowski JM. Autonomous growth of androgen-independent human prostatic carcinoma cells: role of transforming growth factor alpha. Cancer Res. 51(11), 2780–2785 (1991).
   Google Scholar
• Neal DE, Marsh C, Bennett MK et al. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet 1(8425), 366–368 (1985).
   PubMed Web of Science ®Google Scholar
• •The study examined the presence of EGFR in normal and neoplastic human urotheliurn. The findings suggest that the presence of a high intensity of staining for the EGFR in human bladder tumors is associated with poor differentiation and invasion.
   Google Scholar
• Sainsbury JR, Malcolm AJ, Appleton DR, Farndon JR, Harris AL. Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer. j Clin. Pathol 38(11), 1225–1228 (1985).
   Google Scholar
• Veale D, Ashcroft T, Marsh C, Gibson GJ, Harris AL. Epidermal growth factor receptors in non-small cell lung cancer. BE Cancer55(5), 513–516 (1987).
   Google Scholar
• Christen RD, Hom DK, Porter DC et al. Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. j Clin. Invest. 86(5), 1632–1640 (1990).
   Google Scholar
• •This study showed that elements of the signal transduction pathway activated by EGF determined cellular sensitivity to cisplatin and that a cisplatin-resistant phenotype is associated with a defect in this signal transduction pathway.
   Google Scholar
• Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 53(15), 3579–3584 (1993).
   Google Scholar
• Grandis JR, Melhem MF, Gooding WE et al Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival [See Comments]. Natl Cancer Inst. 90(11), 824–832 (1998).
   Google Scholar
• •This study revealed that disease-free survival and cal Ise-specific survival were reduced among patients with higher levels of EGFR or TGF-a. Quantitation of EGFR and TGF-a protein levels in primary HNSCC may be useful in identifying subgroups of patients at high risk of tumor recurrence and in guiding therapy
   Google Scholar
• Shin DM, Ro JY, Hong WK, Hittelman WN. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res. 54 (12), 3153–3159 (1994).
   Google Scholar
• ••This study indicated that EGFR dysregulation occurs in two steps, the moderate up-regulation of EGFR expression in normal epithelium adjacent to tumor and the further up-regulation of EGFR expression in the change from dysplasia to squamous cell carcinoma. Therefore, EGFR dysregulation might be a useful marker for identifying individuals at risk of tumor development and an intermediate end point in chemoprevention trials.
   Google Scholar
• Sunada H, Magun BE, Mendelsohn J, MacLeod CL. Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc. Natl Acad. Sc]. USA 83(11), 3825–3829 (1986).
   Google Scholar
• Goldstein NI, Prewett M, Zuldys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. 1(11), 1311–1318 (1995).
   Google Scholar
• Hoffmann T, Hafner D, Ballo H, Haas I, Bier H. Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines. Anticancer Res. 17(6D), 4419–4425 (1997).
   Google Scholar
• Baselga J, Norton L, Masui H et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J. Natl Cancer Inst. 85(16), 1327–1333 (1993).
   PubMed Web of Science ®Google Scholar
• Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics and tumor angiogenesis [In Process Citation]. Clin. Cancer Res. 6(6), 2166–2174 (2000).
   PubMed Web of Science ®Google Scholar
• •The study suggests that the profound in vivo antitumor activity identified in the xenograft setting when C225 is combined with radiation derives from more than simply the antiproliferative and cell cycle effects of EGFR system inhibition. In addition to antiproliferative growth inhibition, EGFR blockade with C225 appears to influence the capacity of human squamous cell cancer to effect DNA repair after exposure to radiation and to express classic markers of tumor angiogenesis.
   Google Scholar
• Milas L, Mason K, Hunter N et al In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody [See Comments]. Clin. Cancer Res. 6(2), 701–708 (2000).
   Google Scholar
• Baselga J, Pfister D, Cooper MR et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. Oncol 18(4), 904–914 (2000).
   Google Scholar
• •The study evaluated the pharmacokinetics and toxicity of C225 in patients with advanced tumors overexpressing EGFR C225 has dose-dependent pharrnacoldnetics and doses that achieve saturation of systemic clearance are well-tolerated. C225 given in combination with cisplatin has biologic activity at pharmacologically relevant doses.
   Google Scholar
• Shin DM, Donato NJ, Perez-Soler R et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin. Cancer Res. 7(5), 1204–1213 (2001).
   Google Scholar
• ••The Phase lb study with C225 incombination with cisplatin in patients with recurrent HNSCC examined the tumor EGFR saturation dose with C225 and the fate of infused C225. Infused C225 binds and significantly saturates tumor EGFR, which may render a high degree of antitumor activity and provides a novel mechanism for targeting cancer therapy for patients who have EGFR expression in their tumors.
   Google Scholar
• Hong WK, Arquette M, Nabell L, Needle MN, Waksal HW, Herbst RS. Efficacy and safety of the anti-epidermal growth factor antibody IMC- C225, in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck refractory to cisplatin comtaining chemotherapy. Proc. Am. Soc. Clin. Oncol, San Francisco, USA abstract 895 (2001).
   Google Scholar
• Ezekiel MP, Bonner JA, Robert F et al Phase I trial of chimerized anti-epedermal growth factor receptor (Anti-EGFr) antibody in combination with either once-daily or twice-daily irradiation for locally advanced head and neck malignancies. Proc. Am. Soc. Clin. Oncol, Atlanta, USA abstract 1501 (1999).
   Google Scholar
• Ciardiello F, Caputo R, Bianco R et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor- selective tyrosine kinase inhibitor. Clin. Cancer Res. 6(5), 2053–2063 (2000).
   Google Scholar
• •The antiproliferative activity of ZD-1839 alone or in combination with cytotoxic drugs differing in mechanism(s) of action was evaluated in human ovarian, breast and colon cancer cells that coexpress EGFR and TGF-a. A dose-dependent supra-additive increase in growth inhibition was observed when cancer cells were treated with each cytotoxic drug and ZD-1839. These results demonstrate the antitumor effect of this EGFR-selective tyrosine kinase inhibitor.
   Google Scholar
• Baselga J, Herbst R, LoRusso P et al Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: evidence of activity and good tolerablility. Proc. Am. Soc. Clin. Oncol, New Orleans, USA abstract 686 (2000).
   Google Scholar
• Ferry D, Hammond L, Ranson M et al. Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerablitiy and activity: final results from a Phase I study. Proc. Am. Soc. Clin. Oncol, New Orleans, USA abstract 5E (2000).
   Google Scholar
• Shin DM, Nemunaitis J, Zinner RG et al. A Phase I clinical and biomarker study of CI-1033, a novel pan-erbB tyrosine kinase inhibitor in patients with solid tumors. Proc. Am. Soc. Clin. Oncol, San Francisco, USA abstract 324 (2001).
   Google Scholar
• Raybaud-Diogene H, Tetu B, Morency R, Fortin A, Monteil RA. p53 overexpression in head and neck squamous cell carcinoma: review of the literature [See Comments]. Fur. Cancer B Oral Oncol 32B(3), 143–149 (1996).
   Google Scholar
• Bischoff JR, Kim DH, Williams A et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [See Comments] . Science 274 (5286), 373–376 (1996).
   Google Scholar
• Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH. ONYX-015, an ElB gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents [See Comments]. Nature Merl 3(6), 639–645 (1997).
   Google Scholar
• ••The study reported that normal humancells were highly resistant to ONYX-015-mediated, replication-dependent cytolysis while a wide range of human tumor cells, including numerous carcinoma lines with either mutant or normal p53 gene sequences, were efficiently destroyed. Antitumoral efficacy was documented following intratumoral or iv. administration of ONYX-015 to nude mouse-human tumor xenografts; efficacy with ONYX-015 plus chemotherapy (cisplatin, 5- fluorouraci0 was significantly greater than with either agent alone.
   Google Scholar
• Kim D, Hermiston T, McCormick E ONYX-015: clinical data are encouraging [Letter; Comment]. Nature Med. 4 (12), 1341–1342 (1998). A discussion of recent clinical trials of ONYX–015.
   Google Scholar
• Kim D, Nemunaitis J, Ganly I et al. A Phase II trial of intratumoral injection with an E1B-deleted adenovius, ONYX-015, in patients with recurrent, refractory head and neck cancer. Proc. Am. Soc. Clin. Oncol, Los Angeles, USA abstract 1509 (1998).
   Google Scholar
• Ganly I, Eckhardt SG, Rodriguez GI et al. A Phase I study of Onyx-015, an ElB attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer [published erratum appears in Gun. Cancer Res. 6(5), 2120 (2000)1. Clin. Cancer Res. 6(3), 798–806 (2000).
   Google Scholar
• Khuri FR, Nemunaitis J, Ganly I et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer [See Comments]. Nature Med. 6(8), 879–885 (2000).
   Google Scholar
• ••The Phase 11 trial examined thecombination of intratumoral ONYX-015 injection with cisplatin and 5-fluorouracil in patients with recurrent HNSCC. This study reported substantial objective responses, including a high proportion of complete responses, and acceptable toxic effects of the combination.
   Google Scholar
• Clayman GL, El-Naggar AK, Roth JA et al. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 55(1), 1–6 (1995).
   Google Scholar
• •This study showed the prevention of the establishment of tumors in nude mice, in which tumor cells had been subcutaneouly implanted by transiently introducing exogenous wild-type p53 via an adenoviral vector. These effects were vector dose-dependent but independent on the endogenous wild type or mutated p53 status of the cells.
   Google Scholar
• Hamada K, Alemany R, Zhang WW et al. Adenovirus-mediated transfer of a wild- type p53 gene and induction of apoptosis in cervical cancer. Cancer Res. 56(13), 3047–3054 (1996).
   Google Scholar
• Liu TJ, el-Naggar AK, McDonnell TJ et al. Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res. 55(14), 3117–3122 (1995).
   Google Scholar
• Clayman GL, El-Naggar AK, Lippman SM et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J. Clin. Oncol 16(6), 2221–2232 (1998).
   Google Scholar
• •This study examined the safety and therapeutic potential of Ad-p53 in advanced head and neck cancer. Patients were safely injected intratumorally with Ad-p53. Objective antitumor activity was detected in several patients. The infectious Ad-p53 in body fluids was asymptomatic and suggests that systemic or regional treatment may be tolerable.
   Google Scholar
• Beadling C, Guschin D, Witthuhn BA et al Activation of JAK kinases and STAT proteins by interleukin-2 and interferon alpha, but not the T cell antigen receptor, in human T lymphocytes. EMI3013(23), 5605–5615 (1994).
   Google Scholar